Table 2.
Direct oral anticoagulants in development for the prevention of stroke in atrial fibrillation worldwide
| Drug | Manufacturer | Mechanism of action | Phase of development | Frequency of administration | Clinical trial(s) |
|---|---|---|---|---|---|
| Dabigatran etexilate | Boehringer Ingelheim | Thrombin inhibitor | Marketed | Twice daily | RE-LY |
| Apixaban | Pfizer/Bristol-Myers Squibb | Factor Xa inhibitor | Marketed | Twice daily | ARISTOTLE, AVERROES |
| Rivaroxaban | Bayer/Janssen | Factor Xa inhibitor | Marketed | Once daily | ROCKET-AF |
| Edoxaban | Daiichi Sankyo | Factor Xa inhibitor | Marketed (not in Mexico) | Once daily | ENGAGE AF-TIMI 48 |